Drug Abuse Warning Network (DAWN): ED Visits Involving Alcohol Short Report presents the following data from January 2021-September 2023 (1) national estimates and characteristics of alcohol-related ED visits (2) demographics of alcohol-related ED visits (3) percent of ED visits related to alcohol and at least one other substance.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.

This manual offers guidance and tools for identifying mental illness or substance use issues early in children and adolescents in various setting, such as in schools, the juvenile justice and child welfare system, and when receiving primary care.